Oncotelic Therapeutics (OTLC) notifies SEC of delayed 2025 Form 10-K

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. submitted a Form 12b-25 notifying the SEC that its annual report on Form 10-K for the period ended December 31, 2025 could not be filed on time because the company is still compiling the necessary financial information. The company states it expects to file within the permitted extension period.

Key Figures

Fiscal period: December 31, 2025 Notification date: March 31, 2026 Contact phone: (650) 635-7000 +1 more

4 metrics

Fiscal period December 31, 2025 Period ended tied to the delayed Form 10-K

Notification date March 31, 2026 Date the Form 12b-25 was signed by Amit Shah

Contact phone (650) 635-7000 Telephone number provided for inquiries to Amit Shah, CFO

Registrant address 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 Principal executive office address as shown in the notice

Key Terms

Rule 12b-25, Form 12b-25, extension period

3 terms

Rule 12b-25 regulatory

"If the subject report could not be filed without unreasonable effort or expense"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 12b-25 regulatory

"Notification of Late Filing (Check One) Form 10-K"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

extension period regulatory

"The Company expects to file within the extension period"

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

Commission File Number: 000-21990

Notification of Late Filing

(Check One):

☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR

For Period Ended: December 31, 2025

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q
	☐	Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

Part I - Registrant Information

Oncotelic Therapeutics, Inc.

Full Name of Registrant

Mateon Therapeutics, Inc.

Former Name if Applicable

29397 Agoura Road Suite 107

Address of Principal Executive Office (Street and Number)

Agoura Hills, CA 91301

City, State and Zip Code

Part II - Rules 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-(b), the following should be completed. (Check box, if appropriate)

☒ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N- SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

☒ (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Part III - Narrative

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not be file within the prescribed period.

The Company is working on and unable to compile the necessary financial information required to prepare a complete filing. Thus, the Company would be unable to file the annual report in a timely manner without unreasonable effort or expense. The Company expects to file within the extension period.

Part IV - Other Information

(1) Name and telephone number of person to contract in regard to this notification.

Amit Shah		(650)		635-7000
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Oncotelic Therapeutics, Inc.

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 31, 2026	By:	/s/ Amit Shah
		Amit Shah
	Its:	Chief Financial Officer

FAQ

Why did Oncotelic Therapeutics (OTLC) file a Form 12b-25?

Answer: The company could not complete required financial information to prepare its Form 10-K on time. The filing states the registrant is still compiling necessary financial information and therefore seeks the permitted extension to avoid unreasonable effort or expense.

When is the fiscal period covered by the late filing for OTLC?

Answer: The late filing concerns the annual report for the period ended December 31, 2025. The notification identifies that fiscal period as the subject of the delayed Form 10-K submission.

Has Oncotelic indicated when it will file the delayed Form 10-K?

Answer: The company states it expects to file within the extension period. The Form 12b-25 confirms the registrant expects to complete and file the annual report within the time allowed under Rule 12b-25.

Who is the contact for questions about this Form 12b-25 for OTLC?

Answer: The contact listed is Amit Shah, Chief Financial Officer, with phone number (650) 635-7000. The notification provides this name and telephone number for inquiries about the late filing.

Does the filing indicate a change in expected results for the year?

Answer: The filing marks the change-in-results question and indicates no additional quantitative or narrative estimate is provided. It does not attach an anticipated change explanation in the submitted excerpt.